U.S. markets close in 3 hours 7 minutes
  • S&P 500

    4,442.55
    -40.18 (-0.90%)
     
  • Dow 30

    34,548.98
    -166.41 (-0.48%)
     
  • Nasdaq

    13,962.41
    -191.61 (-1.35%)
     
  • Russell 2000

    2,012.80
    -11.24 (-0.56%)
     
  • Crude Oil

    85.23
    -0.32 (-0.37%)
     
  • Gold

    1,833.50
    -9.10 (-0.49%)
     
  • Silver

    24.33
    -0.39 (-1.56%)
     
  • EUR/USD

    1.1348
    +0.0031 (+0.27%)
     
  • 10-Yr Bond

    1.7580
    -0.0750 (-4.09%)
     
  • GBP/USD

    1.3559
    -0.0041 (-0.30%)
     
  • USD/JPY

    113.6480
    -0.4520 (-0.40%)
     
  • BTC-USD

    38,408.52
    -4,686.51 (-10.87%)
     
  • CMC Crypto 200

    902.46
    +659.78 (+271.87%)
     
  • FTSE 100

    7,494.13
    -90.88 (-1.20%)
     
  • Nikkei 225

    27,522.26
    -250.67 (-0.90%)
     

Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

·1 min read

ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.

The presentation will be available for on-demand listening beginning at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021. For those interested in viewing Mr. Eiswirth’s presentation, registration can be accessed here.

About Alimera Sciences, Inc.

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com

For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com